On the other hand, a clinical trial in phase I/II has been finished for EGFRvIII-positive glioma, which consists of a non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine in combination with the EGFRvIII-CAR-T cells and aldesleukin (IL-2) (NCT01454596). Here, IL2 is linked to central nervous system cancer.